Abstract
Hepatocellular carcinoma (HCC) prognosis is very poor, its early treatment is of the utmost importance. Glypican-3 (GPC-3), a membrane-associated heparan sulfate proteoglycan, plays a crucial role in cell proliferation and metastasis, particularly in progression. GPC-3 mediated oncogenesis involves signaling pathways during the malignant transformation of hepatocyte carcinogenesis, with an increasing expression of GPC-3 observed from non-cancerous- to cancerous-tissues, with brown granule-like staining localized in tumor parts of atypical hyperplasia and HCC formation. GPC-3 expression in HCC tissues or circulating blood was associated with tumor size or HBV infection. Circulation of GPC-3-mRNA was detected in HCC patients with relation to TNM stage, periportal cancerous embolus, and extra-hepatic metastasis. After hepatoma, cells were transfected with shRNA, GPC-3 expression or proliferation was inhibited with promoting apoptosis, cell cycle arrested in G1 phase, alteration of hepatoma cell migration and invasion behaviors with down-regulation of β-catenin, IGF-II, and VEGF, and growth of nude mice xenograft tumors was significantly suppressed with the decreases in β -catenin, p-GSK3β, and cyclinD1 expression, suggesting that GPC-3 not only is a specific biomarker for HCC diagnosis, but also is a valuable molecular-target for HCC gene therapy.
Keywords: Diagnosis, glypican-3, hepatocellular carcinoma, signal pathways, targeted-therapy.
Mini-Reviews in Medicinal Chemistry
Title:Down-regulating Glypican-3 Expression: Molecular-targeted Therapy for Hepatocellular Carcinoma
Volume: 14 Issue: 14
Author(s): Zhizhen Dong, Min Yao, Li Wang, Junling Yang and Dengfu Yao
Affiliation:
Keywords: Diagnosis, glypican-3, hepatocellular carcinoma, signal pathways, targeted-therapy.
Abstract: Hepatocellular carcinoma (HCC) prognosis is very poor, its early treatment is of the utmost importance. Glypican-3 (GPC-3), a membrane-associated heparan sulfate proteoglycan, plays a crucial role in cell proliferation and metastasis, particularly in progression. GPC-3 mediated oncogenesis involves signaling pathways during the malignant transformation of hepatocyte carcinogenesis, with an increasing expression of GPC-3 observed from non-cancerous- to cancerous-tissues, with brown granule-like staining localized in tumor parts of atypical hyperplasia and HCC formation. GPC-3 expression in HCC tissues or circulating blood was associated with tumor size or HBV infection. Circulation of GPC-3-mRNA was detected in HCC patients with relation to TNM stage, periportal cancerous embolus, and extra-hepatic metastasis. After hepatoma, cells were transfected with shRNA, GPC-3 expression or proliferation was inhibited with promoting apoptosis, cell cycle arrested in G1 phase, alteration of hepatoma cell migration and invasion behaviors with down-regulation of β-catenin, IGF-II, and VEGF, and growth of nude mice xenograft tumors was significantly suppressed with the decreases in β -catenin, p-GSK3β, and cyclinD1 expression, suggesting that GPC-3 not only is a specific biomarker for HCC diagnosis, but also is a valuable molecular-target for HCC gene therapy.
Export Options
About this article
Cite this article as:
Dong Zhizhen, Yao Min, Wang Li, Yang Junling and Yao Dengfu, Down-regulating Glypican-3 Expression: Molecular-targeted Therapy for Hepatocellular Carcinoma, Mini-Reviews in Medicinal Chemistry 2014; 14 (14) . https://dx.doi.org/10.2174/1389557515666150101105135
DOI https://dx.doi.org/10.2174/1389557515666150101105135 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Approaches for Imaging the Diabetic Pancreas: First Results
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Pre-B Cell Colony Enhancing Factor/NAMPT/Visfatin in Inflammation and Obesity- Related Disorders
Current Pharmaceutical Design Synthesis, Selective Cancer Cytotoxicity and Mechanistic Studies of Novel Analogs of Lantadenes
Anti-Cancer Agents in Medicinal Chemistry Smart Drug-Delivery Systems for Cancer Nanotherapy
Current Drug Targets Meet Our Editorial Board Member:
Anti-Infective Agents Docosahexaenoic Acid (DHA) Sensitizes Brain Tumor Cells to Etoposide-Induced Apoptosis
Current Molecular Medicine Synthesis, Molecular Properties and Evaluation of the Antitumor Activity of 2-Amino-6-Methoxy-4H-Benzo[h]Chromenes, 6-Methoxy-2-Oxo-2HBenzo[ h]Chromene
Current Bioactive Compounds Gemini Surfactant Based Carriers in Gene and Drug Delivery
Current Medicinal Chemistry Immunomodulation in Polytrauma and Polymicrobial Sepsis - Where Do We Stand?
Recent Patents on Inflammation & Allergy Drug Discovery Hypoxia PET Tracers in EBRT Dose Planning in Head and Neck Cancer
Current Radiopharmaceuticals The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Novel Reactions in the Cephalostatin Series
Current Organic Chemistry miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Interferon Therapy in Lung Cancer: Current Perspectives
Current Cancer Therapy Reviews Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Potential Natural Compounds for the Prevention and Treatment of Nonalcoholic Fatty Liver Disease: A Review on Molecular Mechanisms
Current Molecular Pharmacology Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors
Current Topics in Medicinal Chemistry Toward a Discipline of Pharmacoepigenomics
Current Pharmacogenomics CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets